![](/img/cover-not-exists.png)
Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
Delea, Thomas E., Zhang, Xinke, Amdahl, Jordan, Boyko, Diana, Dirnberger, Franziska, Campioni, Marco, Cong, ZeLanguage:
english
Journal:
PharmacoEconomics
DOI:
10.1007/s40273-019-00812-6
Date:
June, 2019
File:
PDF, 1.20 MB
english, 2019